CARS1-AS1: A Drug Target / Disease Biomarker (G100852407)

Target Name: CARS1-AS1

NCBI ID: G100852407

Other Name(s): CARS1 antisense RNA 1 | CARS-AS1 | CARS antisense RNA 1 (non-protein coding)

CARS1-AS1: A Drug Target / Disease Biomarker

CARS1-AS1, also known as S100P, is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the S100 family of proteins, which are known for their role in cell signaling and cytoskeletal organization. S100P is a potential drug target and has been identified as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The S100 family of proteins was first identified in the 1970s based on their ability to interact with the protein p120GAP. This protein is known to play a role in activating the MAPK/ERK signaling pathway, which is involved in a variety of cellular processes, including cell growth, differentiation, and survival. S100P is a member of the S100 family because it contains a catalytic domain that is similar to that of other S100 proteins, as well as a transmembrane region and a cytoplasmic tail.

S100P is involved in a variety of cellular processes, including the regulation of cell adhesion, the assembly and disassembly of mitochondria, and the regulation of the cytoskeleton. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival.

S100P has been shown to be involved in a variety of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that S100P is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting S100P with drugs that can inhibit its activity could be an effective way to treat these diseases.

In addition to its potential as a drug target, S100P has also been identified as a potential biomarker for a variety of diseases. For example, studies have shown that S100P is expressed in the brains of individuals with Alzheimer's disease, and that its levels are associated with the severity of cognitive impairment in these individuals. This suggests that S100P could be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

Another study has shown that S100P is overexpressed in the brains of individuals with Parkinson's disease, and that this increase in S100P levels is associated with the severity of symptoms in these individuals. This suggests that S100P could be a potential drug target for the treatment of Parkinson's disease.

In addition to its potential as a drug target and biomarker, S100P is also involved in the regulation of cellular processes that are important for maintaining cellular homeostasis. This includes the regulation of ion channels, which are responsible for the flow of electrical signals through cells, as well as the regulation of cytoskeletal organization.

Overall, CARS1-AS1, or S100P, is a protein that is involved in a variety of cellular processes that are important for maintaining cellular homeostasis. Its potential as a drug target and biomarker make it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of S100P in cellular processes and its potential as a drug and biomarker.

Protein Name: CARS1 Antisense RNA 1

More Common Targets